Literature DB >> 14679293

Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis.

J Hernández-Rodríguez1, M Segarra, C Vilardell, M Sánchez, A García-Martínez, M J Esteban, C Queralt, J M Grau, A Urbano-Márquez, A Palacín, D Colomer, M C Cid.   

Abstract

OBJECTIVES: To investigate proinflammatory cytokine expression in temporal arteries from patients with giant-cell arteritis (GCA) and to analyse its relationship with the intensity of the initial systemic inflammatory reaction and response to corticosteroid therapy.
METHODS: Quantification of interleukin-1beta (IL-1beta), tumor necrosis factor alpha (TNFalpha), and interleukin-6 (IL-6) mRNA by real-time quantitative PCR in temporal artery samples from 36 patients with biopsy-proven GCA and 11 controls. Immunohistochemical detection of IL-1beta, TNFalpha, and IL-6 in temporal artery sections from 74 patients with GCA and 15 controls. Clinical and biochemical parameters of inflammation as well as the time (weeks) required to reach a maintenance prednisone dose <10 mg/day were recorded.
RESULTS: IL-1beta (13.8 +/- 2.5 vs 5.4 +/- 1.3 relative units, P = 0.012) and IL-6 transcripts (34 +/- 13.7 vs 7.8 +/- 4.5 relative units, P = 0.034) were significantly more abundant in patients with a strong systemic inflammatory response compared with those with no inflammatory parameters. Immunohistochemical scores for IL-1beta (2.7 +/- 0.3 vs 1.9 +/- 0.2, P = 0.018), TNFalpha (3.2 +/- 0.2 vs 2.4 +/- 0.3, P = 0.028) and IL-6 (3 +/- 0.2 vs 2.1 +/- 0.3, P = 0.023) were also significantly higher in patients with strong systemic inflammatory reaction. A significant correlation was found between the amount of tissue TNFalpha mRNA and the time required to reach a maintenance dose of prednisone <10 mg/day (r = 0.586, P = 0.001).
CONCLUSION: GCA patients with a strong systemic inflammatory response, who have been previously shown to be more resistant to corticosteroid therapy, have elevated tissue expression of proinflammatory cytokines IL-1beta, TNFalpha and IL-6. High production of TNFalpha is associated with longer corticosteroid requirements.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14679293     DOI: 10.1093/rheumatology/keh058

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  55 in total

Review 1.  Endothelial cells, antineutrophil cytoplasmic antibodies, and cytokines in the pathogenesis of systemic vasculitis.

Authors:  Maria C Cid; Marta Segarra; Ana García-Martínez; Jose Hernández-Rodríguez
Journal:  Curr Rheumatol Rep       Date:  2004-06       Impact factor: 4.592

Review 2.  New indications for biological therapies.

Authors:  Mariagrazia Catanoso; Nicolò Pipitone; Luca Magnani; Luigi Boiardi; Carlo Salvarani
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

3.  Treatment of refractory temporal arteritis with adalimumab.

Authors:  M Mubashir Ahmed; Eisha Mubashir; Samina Hayat; Marjorie Fowler; Seth Mark Berney
Journal:  Clin Rheumatol       Date:  2006-08-30       Impact factor: 2.980

4.  Infliximab as monotherapy in giant cell arteritis.

Authors:  Imad Uthman; Nadim Kanj; Samir Atweh
Journal:  Clin Rheumatol       Date:  2005-05-18       Impact factor: 2.980

Review 5.  [Current therapeutic options for giant cell arteritis].

Authors:  E Wipfler-Freissmuth; J Loock; F Moosig; C Dejaco; C Duftner; M Schirmer
Journal:  Z Rheumatol       Date:  2009-03       Impact factor: 1.372

Review 6.  Biologic Therapy for the Treatment of Giant Cell Arteritis.

Authors:  Rochella A Ostrowski; Melissa R Bussey; Rodney Tehrani; Walter Jay
Journal:  Neuroophthalmology       Date:  2014-04-02

7.  An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy.

Authors:  Chie Miyabe; Yoshishige Miyabe; Klemen Strle; Nancy D Kim; John H Stone; Andrew D Luster; Sebastian Unizony
Journal:  Ann Rheum Dis       Date:  2016-12-07       Impact factor: 19.103

8.  The promotion of functional urinary bladder regeneration using anti-inflammatory nanofibers.

Authors:  Matthew I Bury; Natalie J Fuller; Jay W Meisner; Matthias D Hofer; Matthew J Webber; Lesley W Chow; Sheba Prasad; Hatim Thaker; Xuan Yue; Vani S Menon; Edward C Diaz; Samuel I Stupp; Earl Y Cheng; Arun K Sharma
Journal:  Biomaterials       Date:  2014-08-18       Impact factor: 12.479

9.  Successful treatment of refractory giant cell arteritis with etanercept.

Authors:  Masaaki Fujita; Yuya Tabuchi; Masato Yagita
Journal:  Rheumatol Int       Date:  2016-07-01       Impact factor: 2.631

Review 10.  Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.

Authors:  Christian Dejaco; Elisabeth Brouwer; Justin C Mason; Frank Buttgereit; Eric L Matteson; Bhaskar Dasgupta
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.